• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
EDUCATIONAL SERIES ON THE SPECIALIST VALVE CLINIC: Challenges in the diagnosis and management of valve disease: the case for the specialist valve clinic.专科瓣膜诊所教育系列:瓣膜疾病诊断与管理中的挑战:专科瓣膜诊所的情况
Echo Res Pract. 2019 Dec 1;6(4):T1-T6. doi: 10.1530/ERP-19-0041.
2
Unmet needs in valvular heart disease.瓣膜性心脏病的未满足需求。
Eur Heart J. 2023 Jun 1;44(21):1862-1873. doi: 10.1093/eurheartj/ehad121.
3
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).心房颤动合并心脏瓣膜病的抗栓治疗:欧洲心律协会(EHRA)和欧洲心脏病学会血栓工作组的联合共识文件,得到 ESC 心脏瓣膜病工作组、南非心脏协会(SA Heart)、心律学会(HRS)、亚太心律学会(APHRS)、南非心脏协会(SA Heart)和拉丁美洲心脏刺激和电生理学会(SOLEACE)的认可。
Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240.
4
5
ESC Working Group on Valvular Heart Disease position paper--heart valve clinics: organization, structure, and experiences.ESC 工作组关于瓣膜性心脏病立场文件——心脏瓣膜诊所:组织、结构和经验。
Eur Heart J. 2013 Jun;34(21):1597-606. doi: 10.1093/eurheartj/ehs443. Epub 2013 Jan 4.
6
Five-year epidemiological survey of valvular heart disease: changes in morbidity, etiological spectrum and management in a cardiovascular center of Southern China.心脏瓣膜病的五年流行病学调查:中国南方某心血管中心发病率、病因谱及治疗的变化
J Thorac Dis. 2014 Dec;6(12):1724-30. doi: 10.3978/j.issn.2072-1439.2014.11.21.
7
Lack of progress in valvular heart disease in the pre-transcatheter aortic valve replacement era: increasing deaths and minimal change in mortality rate over the past three decades.在经导管主动脉瓣置换术时代之前,瓣膜性心脏病的进展缓慢:在过去的三十年中,死亡率不断上升,而死亡率的变化极小。
Am Heart J. 2014 Apr;167(4):562-567.e2. doi: 10.1016/j.ahj.2013.12.030. Epub 2014 Jan 14.
8
Narrative review of the role of artificial intelligence to improve aortic valve disease management.人工智能在改善主动脉瓣疾病管理中作用的叙述性综述。
J Thorac Dis. 2021 Jan;13(1):396-404. doi: 10.21037/jtd-20-1837.
9
The future of valvular heart disease assessment and therapy.瓣膜性心脏病评估和治疗的未来。
Lancet. 2024 Apr 20;403(10436):1590-1602. doi: 10.1016/S0140-6736(23)02754-X. Epub 2024 Mar 27.
10
The "Heart Valve Clinic" Pathway for the Management of Frail Patients With Valvular Heart Disease: From "One for All" to "All for One".“心脏瓣膜诊所”对老年瓣膜性心脏病患者的管理路径:从“一刀切”到“一人一策”
Crit Pathw Cardiol. 2019 Jun;18(2):61-65. doi: 10.1097/HPC.0000000000000179.

引用本文的文献

1
A New Benchmark for Modern Management of Valvular Heart Disease: The Whole-Life Cycle Management System.心脏瓣膜病现代管理的新基准:全生命周期管理系统
JACC Asia. 2025 May;5(5):609-632. doi: 10.1016/j.jacasi.2025.01.017. Epub 2025 Apr 8.
2
Establishing a Novel Diagnostic Framework Using Handheld Point-of-Care Focused-Echocardiography (HoPE) for Acute Left-Sided Cardiac Valve Emergencies: A Bayesian Approach for Emergency Physicians in Resource-Limited Settings.建立一种使用手持式即时焦点超声心动图(HoPE)诊断急性左侧心脏瓣膜急症的新型诊断框架:一种针对资源有限环境中急诊医生的贝叶斯方法。
Diagnostics (Basel). 2023 Aug 3;13(15):2581. doi: 10.3390/diagnostics13152581.
3
EDUCATIONAL SERIES ON THE SPECIALIST VALVE CLINIC: How to run a specialist valve clinic: a collaborative series from the British Heart Valve Society and the British Society of Echocardiography.心脏瓣膜专科门诊教育系列:如何运营心脏瓣膜专科门诊:英国心脏瓣膜学会和英国超声心动图学会联合系列报道
Echo Res Pract. 2019 Dec 1;6(4):E1-E2. doi: 10.1530/ERP-19-0035.

本文引用的文献

1
Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe.在欧洲,数据中继的便利性及其对严重主动脉瓣狭窄治疗的影响。
J Am Heart Assoc. 2019 Oct;8(19):e013160. doi: 10.1161/JAHA.119.013160. Epub 2019 Sep 24.
2
Symptoms, disease severity and treatment of adults with a new diagnosis of severe aortic stenosis.成人新发严重主动脉瓣狭窄的症状、疾病严重程度和治疗。
Heart. 2019 Nov;105(22):1709-1716. doi: 10.1136/heartjnl-2019-314940. Epub 2019 Jul 13.
3
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.经皮球囊扩张式主动脉瓣置换术治疗低危患者。
N Engl J Med. 2019 May 2;380(18):1695-1705. doi: 10.1056/NEJMoa1814052. Epub 2019 Mar 16.
4
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.经导管主动脉瓣置换术治疗低危患者的自膨式瓣膜。
N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16.
5
Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis.主动脉瓣狭窄中心肌纤维化的影像学表现及影响。
JACC Cardiovasc Imaging. 2019 Feb;12(2):283-296. doi: 10.1016/j.jcmg.2018.11.026.
6
Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics.心脏瓣膜门诊随访的无症状主动脉瓣狭窄患者的结局。
JAMA Cardiol. 2018 Nov 1;3(11):1060-1068. doi: 10.1001/jamacardio.2018.3152.
7
Transcatheter Mitral-Valve Repair in Patients with Heart Failure.经导管二尖瓣修复术治疗心力衰竭患者。
N Engl J Med. 2018 Dec 13;379(24):2307-2318. doi: 10.1056/NEJMoa1806640. Epub 2018 Sep 23.
8
Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.经皮修复或药物治疗继发性二尖瓣反流。
N Engl J Med. 2018 Dec 13;379(24):2297-2306. doi: 10.1056/NEJMoa1805374. Epub 2018 Aug 27.
9
Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes.经导管二尖瓣修复术治疗功能性二尖瓣反流:1 年结果。
Eur Heart J. 2019 Feb 1;40(5):466-472. doi: 10.1093/eurheartj/ehy424.
10
Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting.社区诊断患者的三尖瓣反流负担。
JACC Cardiovasc Imaging. 2019 Mar;12(3):433-442. doi: 10.1016/j.jcmg.2018.06.014. Epub 2018 Aug 15.

专科瓣膜诊所教育系列:瓣膜疾病诊断与管理中的挑战:专科瓣膜诊所的情况

EDUCATIONAL SERIES ON THE SPECIALIST VALVE CLINIC: Challenges in the diagnosis and management of valve disease: the case for the specialist valve clinic.

作者信息

Messika-Zeitoun David, Burwash Ian G, Mesana Thierry

机构信息

University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

出版信息

Echo Res Pract. 2019 Dec 1;6(4):T1-T6. doi: 10.1530/ERP-19-0041.

DOI:10.1530/ERP-19-0041
PMID:31729210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6865354/
Abstract

Valvular heart disease (VHD) is responsible for a major societal and economic burden. Incidence and prevalence of VHD are high and increase as the population ages, creating the next epidemic. In Western countries, the etiology is mostly degenerative or functional disease and strikes an elderly population with multiple comorbidities. Epidemiological studies have shown that VHD is commonly underdiagnosed, leading to patients presenting late in their disease course, to an excess risk of mortality and morbidity and to a missed opportunity for intervention. Once diagnosed, VHD is often undertreated with patients unduly denied intervention, the only available curative treatment. This gap between current recommendations and clinical practice and the marked under-treatment is at least partially related to poor knowledge of current National and International Societies Guidelines. Development of a valvular heart team involving multidisciplinary valve specialists including clinicians, imaging specialists, interventional cardiologists and surgeons is expected to fill these gaps and to offer an integrated care addressing all issues of patient management from evaluation, risk-assessment, decision-making and performance of state-of-the-art surgical and transcatheter interventions. The valvular heart team will select the right treatment for the right patient, improving cost-effectiveness and ultimately patients' outcomes.

摘要

心脏瓣膜病(VHD)造成了重大的社会和经济负担。VHD的发病率和患病率很高,且随着人口老龄化而上升,形成下一场流行病。在西方国家,其病因大多是退行性或功能性疾病,侵袭患有多种合并症的老年人群。流行病学研究表明,VHD常常未被诊断出来,导致患者在疾病进程后期才就诊,增加了死亡和发病风险,也错失了干预时机。一旦确诊,VHD往往治疗不足,患者被不恰当地拒绝接受唯一可用的治愈性治疗——干预。当前建议与临床实践之间的这种差距以及显著的治疗不足至少部分与对当前国家和国际学会指南的了解不足有关。组建一个由包括临床医生、影像专家、介入心脏病专家和外科医生在内的多学科瓣膜专家组成的心脏瓣膜团队,有望填补这些差距,并提供综合护理,解决从评估、风险评估、决策到实施最先进的外科和经导管干预等患者管理的所有问题。心脏瓣膜团队将为合适的患者选择合适的治疗方法,提高成本效益,并最终改善患者的治疗效果。